These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 24664620)

  • 1. Efficacy of liraglutide in a real-life cohort.
    Heymann A; Maor Y; Goldstein I; Todorova L; Schertz-Sternberg P; Karasik A
    Diabetes Ther; 2014 Jun; 5(1):193-206. PubMed ID: 24664620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study.
    Jain AB; Kanters S; Khurana R; Kissock J; Severin N; Stafford SG
    Diabetes Ther; 2021 Feb; 12(2):527-536. PubMed ID: 33367981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
    Buse JB; Vilsbøll T; Thurman J; Blevins TC; Langbakke IH; Bøttcher SG; Rodbard HW;
    Diabetes Care; 2014 Nov; 37(11):2926-33. PubMed ID: 25114296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy.
    Thayer S; Wei W; Buysman E; Brekke L; Crown W; Grabner M; Raparla S; Quimbo R; Cziraky MJ; Hu W; Cuddihy R
    Adv Ther; 2013 Dec; 30(12):1128-40. PubMed ID: 24293131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis.
    Lorenzi M; Ploug UJ; Langer J; Skovgaard R; Zoratti M; Jansen J
    Diabetes Ther; 2017 Feb; 8(1):85-99. PubMed ID: 27995594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study.
    Saunders WB; Nguyen H; Kalsekar I
    Diabetes Metab Syndr Obes; 2016; 9():217-23. PubMed ID: 27486339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review.
    Ostawal A; Mocevic E; Kragh N; Xu W
    Diabetes Ther; 2016 Sep; 7(3):411-38. PubMed ID: 27350545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden.
    Lind M; Matsson PO; Linder R; Svenningsson I; Jørgensen L; Ploug UJ; Gydesen H; Dorkhan M; Larsen S; Johansson G
    Diabetes Ther; 2016 Jun; 7(2):321-33. PubMed ID: 27216947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program.
    Khunti K; Mohan V; Jain SM; Boesgaard TW; Begtrup K; Sethi B
    Diabetes Ther; 2017 Jun; 8(3):673-682. PubMed ID: 28332144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies.
    Blonde L; Russell-Jones D
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():26-34. PubMed ID: 19878259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus.
    Rondanelli M; Perna S; Astrone P; Grugnetti A; Solerte SB; Guido D
    Patient Prefer Adherence; 2016; 10():407-13. PubMed ID: 27069358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Network meta-analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg.
    Fahrbach JL; Fu H; Shurzinske L; Skrivanek Z; Martin S
    Int J Clin Pract; 2016 Mar; 70(3):218-21. PubMed ID: 26916354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
    Frandsen CS; Dejgaard TF; Holst JJ; Andersen HU; Thorsteinsson B; Madsbad S
    Diabetes Care; 2015 Dec; 38(12):2250-7. PubMed ID: 26486191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study.
    Mezquita-Raya P; Reyes-Garcia R; Moreno-Perez O; Escalada-San Martin J; Ángel Rubio Herrera M; Lopez de la Torre Casares M
    Diabetes Ther; 2015 Jun; 6(2):173-85. PubMed ID: 26055216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes.
    Melzer-Cohen C; Chodick G; Husemoen LLN; Rhee N; Shalev V; Karasik A
    Diabetes Ther; 2019 Apr; 10(2):683-696. PubMed ID: 30815829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Effectiveness of Liraglutide in Association with Patients' Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study.
    Berkovic MC; Bilic-Curcic I; Herman Mahecic D; Gradiser M; Grgurevic M; Bozek T
    Diabetes Ther; 2017 Dec; 8(6):1297-1308. PubMed ID: 29076038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial.
    Retnakaran R; Kramer CK; Choi H; Swaminathan B; Zinman B
    Diabetes Care; 2014 Dec; 37(12):3270-8. PubMed ID: 25249651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs).
    Desouza C; Kirk AR; Mangla KK; Wolden ML; Lingvay I
    BMJ Open Diabetes Res Care; 2020 Dec; 8(2):. PubMed ID: 33376084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.